M

Mevo

Health Tech & Medtech · Presidente Prudente, Brazil · Founded 2017

Mevo is a Brazilian health-tech firm, founded in 2017 by Pedro Dias, Lucas Lacerda, and Antonio Carlos Endrigo, that is positioned to overhaul the country's healthcare infrastructure. The company, formerly known as Nexodata, was established to address the inefficiencies of a system reliant on paper-based prescriptions. Mevo provides a digital platform that enables healthcare professionals to issue electronic prescriptions for medications, exams, and other health documents, which are then sent directly to a patient's mobile device via SMS or WhatsApp. The firm's business model is primarily B2B2C, providing its digital prescription software free of charge to hospitals and healthcare institutions to integrate into their physician networks. This strategy has facilitated rapid adoption, with the platform being used in over 1,000 hospitals by clients such as Rede D'Or, Sírio-Libanês, and Oncoclínicas. Monetization began in 2022 through a marketplace embedded within the platform. After receiving a digital prescription, patients can opt to purchase the required medications through Mevo's interface. This marketplace functions as both a first-party (1P) online pharmacy, Mevo Farma, which operates its own logistics hub in São Paulo for rapid delivery, and a third-party marketplace connecting patients with a network of partner pharmacies. All of Brazil's 80,000+ pharmacies are equipped to process a Mevo prescription. Mevo's platform delivers tangible benefits across the healthcare ecosystem. For patients, it simplifies access to medication and is designed to improve treatment adherence. Healthcare professionals benefit from clinical support tools that reduce administrative tasks and have been shown to decrease detrimental drug interactions by 33% in a one-year study. For providers like hospitals and clinics, the system structures previously inaccessible data from prescriptions, enabling real-time analysis to better serve patients. The company has achieved significant traction, serving over 10 million patients and partnering with more than 300 hospitals and clinics. Financially, Mevo is well-capitalized, having raised approximately $39.3 million over four funding rounds, including a notable Series B in 2024. This round was led by Matrix, a San Francisco-based venture capital firm, marking its first investment in Brazil. The funding also attracted participation from Jefferson River Capital and notable angel investors like Elliot Cohen, a co-founder of PillPack and former Amazon Pharmacy leader. Other significant investors across its funding history include Hospital Israelita Albert Einstein, Floating Point, and Mercado Livre's MELI Fund. These funds are allocated to expand its partner network, enhance the technology platform, and explore services beyond prescription fulfillment. Keywords: digital prescriptions, e-prescription, health-tech, Brazil healthcare, online pharmacy, medication delivery, pharmacy marketplace, telemedicine, electronic medical records, clinical decision support, hospital software, patient adherence, Rede D'Or, Sírio-Libanês, Pedro Dias, Lucas Lacerda, Matrix investment, Floating Point, Mevo Farma, healthcare infrastructure, digital health Brazil, medication management